<DOC>
	<DOCNO>NCT03072043</DOCNO>
	<brief_summary>The main purpose study determine safe recommend dose APR-246 combination azacitidine well see combination therapy improve overall survival .</brief_summary>
	<brief_title>Phase 1b/2 Safety Efficacy APR-246 w/Azacitidine tx TP53 Mutant Myeloid Neoplasms</brief_title>
	<detailed_description>Participants treat total 6 cycle . For participant respond stable disease follow cycle 6 , treatment may continue one follow criterion applies : - Inter-current illness prevents administration treatment , - Unacceptable adverse event ( ) , - Participant decide withdraw study , - General specific change participant 's condition render participant unacceptable treatment judgment investigator . - Evidence disease progression International Working Group ( IWG ) 2006 criterion . Participants wish continue treatment time disease assessment end cycle 6 complete end treatment visit upon completion cycle 6 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Has sign Informed Consent ( ICF ) able comply protocol requirement . Has adequate organ function accord study protocol guideline . Age ≥18 year time signing informed consent form . Documented diagnosis myelodysplastic syndrome ( MDS ) , MDS/ myeloproliferative neoplasm ( MPN ) , chronic myelomonocytic leukemia ( CMML ) oligoblastic AML ( 2030 % myeloblast ) World Health Organization ( WHO ) criterion . Documentation TP53 gene mutation NGS base central local evaluation . For TP53 mutant patient low risk MDS ( i.e. , low intermediate1 risk International Prognostic Scoring System ( IPSS ) ) isolate deletion 5q ( del ( 5q ) ) , failure prior treatment least 4 full cycle lenalidomide define response treatment , loss response time point , progressive disease , intolerance therapy . An Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 require . If childbearing potential , negative pretreatment serum pregnancy test . If childbearing potential , willing use effective form contraception hormonal birth control , intrauterine device double barrier method chemotherapy treatment least six month thereafter . Known history HIV active hepatitis B active hepatitis C infection ( test mandatory ) . Has follow cardiac abnormality ( determine treat MD ) : a. Symptomatic congestive heart failure ; b. Myocardial infarction less equal 6 month prior enrollment ; c. Unstable angina pectoris ; d. Serious uncontrolled cardiac arrhythmia ; e. QTc ≥ 480 msec . Concomitant malignancies previous malignancy less 1year disease free interval time sign consent . Potential participant adequately resect basal squamous cell carcinoma skin , adequately resect carcinoma situ ( e.g. , cervix ) may enroll irrespective time diagnosis . Use cytotoxic chemotherapeutic agent , experimental agent ( agent commercially available ) treatment MDS , MDS/MPN , CMML AML within 14 day first day study drug treatment . No concurrent use erythroid stimulating agent , GCSF , GMCSF allow study except case febrile neutropenia GCSF use short term . Growth factor must stop 14 day prior study . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
	<keyword>TP53 mutant myelodysplastic syndrome</keyword>
	<keyword>MDS/myeloproliferative neoplasm ( MPN )</keyword>
	<keyword>chronic myelomonocytic leukemia ( CMML )</keyword>
	<keyword>acute myeloid leukemia ( AML )</keyword>
</DOC>